Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Immunology

Background:

• Macrophage inflammatory protein-1alpha (MIP-1alpha) plays a role in inflammatory and immune responses.
• Chemokine receptor 5 (CCR5) is a key target for modulating inflammatory diseases.
• Understanding MIP-1alpha/CCR5 interactions is crucial for developing novel therapeutics.

Purpose of the Study:

• To design and synthesize novel hydroxylated derivatives of beta-substituted (2R,3R)-2-amino-3-hydroxypropionic acid.
• To evaluate the inhibitory activity of these compounds against MIP-1alpha binding to human CCR5.
• To compare the efficacy of hydroxylated versus non-hydroxylated derivatives and other isomers.

Main Methods:

• Chemical synthesis of hydroxylated and non-hydroxylated compound series.
• In vitro assays to measure the binding affinity of MIP-1alpha to human CCR5.
• Comparative analysis of inhibitory activities across different isomers and derivatives.

Main Results:

• Synthesized hydroxylated derivatives based on oxidative metabolite information.
• Compounds derived from beta-substituted (2R,3R)-2-amino-3-hydroxypropionic acid demonstrated improved inhibitory activity.
• Enhanced inhibition was observed compared to non-hydroxylated analogs and other stereoisomers.

Conclusions:

• Hydroxylation of specific beta-substituted amino acid derivatives enhances inhibitory activity against MIP-1alpha/CCR5 binding.
• These findings suggest a promising avenue for developing targeted therapies for CCR5-mediated inflammatory conditions.
• The designed compounds represent potential drug candidates for inflammatory and autoimmune diseases.